Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,951-2,000 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_B7,8 | Lung | Primary cancer | 201 | Tumor/Malignant | 59.7% | 0.67 | 0.55 |
| NSCLC_38242124__IMC__88_B7,9 | Lung | Primary cancer | 367 | Tumor/Malignant | 54.0% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__88_B8,1 | Lung | Primary cancer | 2,911 | Stromal | 35.9% | 0.85 | 0.40 |
| NSCLC_38242124__IMC__88_B8,10 | Lung | Primary cancer | 3,536 | Tumor/Malignant | 59.0% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_B8,12 | Lung | Primary cancer | 3,920 | Tumor/Malignant | 54.4% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__88_B8,13 | Lung | Primary cancer | 4,127 | Tumor/Malignant | 58.4% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__88_B8,14 | Lung | Primary cancer | 543 | Tumor/Malignant | 42.7% | 0.86 | 0.40 |
| NSCLC_38242124__IMC__88_B8,16 | Lung | Primary cancer | 3,380 | Tumor/Malignant | 48.2% | 1.00 | 0.05 |
| NSCLC_38242124__IMC__88_B8,2 | Lung | Primary cancer | 3,799 | Tumor/Malignant | 40.2% | 0.98 | 0.15 |
| NSCLC_38242124__IMC__88_B8,3 | Lung | Primary cancer | 3,990 | Tumor/Malignant | 35.7% | 0.93 | 0.24 |
| NSCLC_38242124__IMC__88_B8,4 | Lung | Primary cancer | 3,835 | Tumor/Malignant | 63.0% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__88_B8,5 | Lung | Primary cancer | 4,608 | Stromal | 29.2% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__88_B8,6 | Lung | Primary cancer | 3,347 | Tumor/Malignant | 51.4% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_B8,7 | Lung | Primary cancer | 2,969 | Tumor/Malignant | 43.3% | 0.95 | 0.22 |
| NSCLC_38242124__IMC__88_B8,8 | Lung | Primary cancer | 2,955 | Stromal | 40.6% | 0.47 | 0.75 |
| NSCLC_38242124__IMC__88_B8,9 | Lung | Primary cancer | 3,102 | Tumor/Malignant | 52.2% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__88_C1,1 | Lung | Primary cancer | 2,352 | Stromal | 30.7% | 0.73 | 0.66 |
| NSCLC_38242124__IMC__88_C1,10 | Lung | Primary cancer | 2,998 | Tumor/Malignant | 47.4% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__88_C1,11 | Lung | Primary cancer | 2,439 | Tumor/Malignant | 47.2% | 0.93 | 0.25 |
| NSCLC_38242124__IMC__88_C1,12 | Lung | Primary cancer | 3,362 | Tumor/Malignant | 37.6% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__88_C1,13 | Lung | Primary cancer | 2,658 | Tumor/Malignant | 27.6% | 0.88 | 0.33 |
| NSCLC_38242124__IMC__88_C1,14 | Lung | Primary cancer | 2,535 | Tumor/Malignant | 38.0% | 0.87 | 0.36 |
| NSCLC_38242124__IMC__88_C1,15 | Lung | Primary cancer | 2,630 | Tumor/Malignant | 53.7% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__88_C1,2 | Lung | Primary cancer | 1,438 | Stromal | 36.0% | 0.80 | 0.49 |
| NSCLC_38242124__IMC__88_C1,3 | Lung | Primary cancer | 4,167 | Tumor/Malignant | 33.2% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__88_C1,5 | Lung | Primary cancer | 2,891 | Tumor/Malignant | 48.9% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__88_C1,6 | Lung | Primary cancer | 2,689 | Tumor/Malignant | 41.7% | 0.53 | 0.84 |
| NSCLC_38242124__IMC__88_C1,7 | Lung | Primary cancer | 125 | Stromal | 52.0% | 0.40 | 0.78 |
| NSCLC_38242124__IMC__88_C1,8 | Lung | Primary cancer | 4,431 | Immune | 48.0% | 0.88 | 0.35 |
| NSCLC_38242124__IMC__88_C1,9 | Lung | Primary cancer | 1,768 | Immune | 32.1% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__88_C2,1 | Lung | Primary cancer | 2,758 | Tumor/Malignant | 57.2% | 0.96 | 0.10 |
| NSCLC_38242124__IMC__88_C2,10 | Lung | Primary cancer | 3,307 | Tumor/Malignant | 35.1% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__88_C2,11 | Lung | Primary cancer | 1,306 | Stromal | 31.2% | 0.81 | 0.53 |
| NSCLC_38242124__IMC__88_C2,12 | Lung | Primary cancer | 3,372 | Tumor/Malignant | 36.8% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__88_C2,13 | Lung | Primary cancer | 1,907 | Tumor/Malignant | 49.6% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__88_C2,14 | Lung | Primary cancer | 2,427 | Stromal | 30.0% | 0.80 | 0.46 |
| NSCLC_38242124__IMC__88_C2,15 | Lung | Primary cancer | 1,403 | Tumor/Malignant | 29.8% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__88_C2,2 | Lung | Primary cancer | 5,346 | Immune | 63.3% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_C2,3 | Lung | Primary cancer | 3,214 | Tumor/Malignant | 26.1% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__88_C2,6 | Lung | Primary cancer | 2,389 | Tumor/Malignant | 34.8% | 0.51 | 0.88 |
| NSCLC_38242124__IMC__88_C2,8 | Lung | Primary cancer | 3,538 | Stromal | 39.4% | 0.90 | 0.33 |
| NSCLC_38242124__IMC__88_C2,9 | Lung | Primary cancer | 2,497 | Tumor/Malignant | 32.0% | 0.95 | 0.23 |
| NSCLC_38242124__IMC__88_C3,1 | Lung | Primary cancer | 2,992 | Tumor/Malignant | 28.2% | 0.51 | 0.75 |
| NSCLC_38242124__IMC__88_C3,11 | Lung | Primary cancer | 2,885 | Tumor/Malignant | 54.9% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__88_C3,12 | Lung | Primary cancer | 5,783 | Immune | 81.8% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__88_C3,14 | Lung | Primary cancer | 4,881 | Immune | 93.0% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__88_C3,15 | Lung | Primary cancer | 682 | Tumor/Malignant | 28.2% | 0.48 | 0.91 |
| NSCLC_38242124__IMC__88_C3,2 | Lung | Primary cancer | 1,570 | Stromal | 25.4% | 0.34 | 1.02 |
| NSCLC_38242124__IMC__88_C3,3 | Lung | Primary cancer | 383 | Tumor/Malignant | 42.8% | 0.89 | 0.20 |
| NSCLC_38242124__IMC__88_C3,4 | Lung | Primary cancer | 133 | Stromal | 56.4% | 0.64 | 0.65 |